Ysios Capital, a Spanish venture capital firm specialising in life sciences, today announced the launch of InceptionBio, a new fund with a tarobtain size of €100 million focapplyd on BioTech company creation and early-stage project development.
The fund has already completed its first closing, with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte programme, which supports investment in high-potential innovative companies. Joan Perelló, Managing Partner at Ysios Capital, will lead the fund, alongside partner Arturo Urrios.
“Spain has world-class science and a unique opportunity to translate that science into globally impactful BioTech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients,” stated Joan Perelló, Managing Partner at Ysios Capital.
Founded in 2008, Ysios Capital manages over €400 million in assets through its three venture capital funds and also acts as investment advisor to Telescope Biotech Fund, a listed BioTech fund managed by Andbank Wealth Management.
The VC firm offers private equity funding to early- and mid-stage life science companies developing treatments that significantly impact patients, focutilizing on areas with high unmet medical necessarys.
InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. The new fund will primarily invest in technology transfer opportunities and early-stage companies. This will enable Ysios to work closely with universities, research centres, and scientific entrepreneurs to accelerate the translation of scientific discoveries into new therapies.
CDTI-Innvierte’s support enhances public-private collaboration in a key sector for Spain’s BioTech ecosystem. The VC firm states that this supports in accelerating technology transfer, encouraging the development of high-growth, innovation-driven companies, and boosting the competitiveness of Spain’s R&D system.
The fund currently has a pipeline of investment opportunities under advanced review and aims to support the creation of at least three new BioTech companies in 2026.
According to Ysios, InceptionBio’s strategy involves creating new companies based on scientific assets from universities and research centres, while also identifying and attracting international assets that can be developed in Spain.
Through this strategy, Ysios plans to bolster the Spanish BioTech ecosystem and establish Spain as a leading hub in this sector. This new strategy complements Ysios Capital’s investment approach and broadens early-stage engagement. With the launch of InceptionBio, Ysios aims to further expand its ability to support biomedical innovation, starting from company creation through later-stage development.
“We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital necessaryed to develop them. InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain,” stated Arturo Urrios, Partner at Ysios Capital.
Ysios Capital has invested in more than 40 BioTech companies and has completed six NASDAQ exits and ten M&A transactions. The firm has participated in major Spanish BioTech transactions, including investments in Tigenix/Cellerix, Sanifit, STAT-Diagnostica, Ona Therapeutics, SpliceBio, and Minoryx Therapeutics. It has also played a key role in prominent deals like Takeda’s acquisition of Tigenix (€450 million), Qiagen’s purchase of STAT-Diagnostica (€172 million), and Vifor Pharma’s Sanifit acquisition (€375 million).
Leave a Reply